# Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

> **NCT05142241** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 14 (actual)

## Conditions studied

- Adrenal Gland Pheochromocytoma
- Hematopoietic and Lymphatic System Neoplasm
- Malignant Solid Neoplasm
- Paraganglioma

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Talazoparib
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05142241
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-11
- **Primary completion:** 2025-09-26
- **Final completion:** 2026-09-29
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05142241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05142241, "Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05142241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*